Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Majumder

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Leukemia|July 28, 2016
Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemiaS Eldfors, H Kuusanmäki, M Kontro, et al.
Oncotarget|December 13, 2017
Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signalingHeikki Kuusanmäki, Olli Dufva, Elina Parri, et al.
Blood Cancer Journal|May 2, 2015
Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testingP O Pietarinen, T Pemovska, M Kontro, et al.
Leukemia|November 12, 2016
Enhanced sensitivity to glucocorticoids in cytarabine-resistant AMLD Malani, A Murumägi, B Yadav, et al.
Hemasphere|March 4, 2022
The Peptide-Drug Conjugate Melflufen Modulates the Unfolded Protein Response of Multiple Myeloma and Amyloidogenic Plasma Cells and Induces Cell DeathKen Flanagan, Romika Kumari, Juho J Miettinen, et al.
Leukemia|August 9, 2016
HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemiaM Kontro, A Kumar, M M Majumder, et al.
Haematologica|August 24, 2019
Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell typesMuntasir M Majumder, Aino-Maija Leppä, Monica Hellesøy, et al.
Physical Review Letters|June 23, 2018
Breakdown of Magnetic Order in the Pressurized Kitaev Iridate β-Li_{2}IrO_{3}M Majumder, R S Manna, G Simutis, et al.
Cancers|April 3, 2021
Aminopeptidase Expression in Multiple Myeloma Associates with Disease Progression and Sensitivity to MelflufenJuho J Miettinen, Romika Kumari, Gunnhildur Asta Traustadottir, et al.
Blood|June 17, 2017
JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AMLRiikka Karjalainen, Tea Pemovska, Mihaela Popa, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Leukemia|July 28, 2016
Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemiaS Eldfors, H Kuusanmäki, M Kontro, et al.
Oncotarget|December 13, 2017
Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signalingHeikki Kuusanmäki, Olli Dufva, Elina Parri, et al.
Blood Cancer Journal|May 2, 2015
Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testingP O Pietarinen, T Pemovska, M Kontro, et al.
Leukemia|November 12, 2016
Enhanced sensitivity to glucocorticoids in cytarabine-resistant AMLD Malani, A Murumägi, B Yadav, et al.
Hemasphere|March 4, 2022
The Peptide-Drug Conjugate Melflufen Modulates the Unfolded Protein Response of Multiple Myeloma and Amyloidogenic Plasma Cells and Induces Cell DeathKen Flanagan, Romika Kumari, Juho J Miettinen, et al.
Leukemia|August 9, 2016
HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemiaM Kontro, A Kumar, M M Majumder, et al.
Haematologica|August 24, 2019
Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell typesMuntasir M Majumder, Aino-Maija Leppä, Monica Hellesøy, et al.
Physical Review Letters|June 23, 2018
Breakdown of Magnetic Order in the Pressurized Kitaev Iridate β-Li_{2}IrO_{3}M Majumder, R S Manna, G Simutis, et al.
Cancers|April 3, 2021
Aminopeptidase Expression in Multiple Myeloma Associates with Disease Progression and Sensitivity to MelflufenJuho J Miettinen, Romika Kumari, Gunnhildur Asta Traustadottir, et al.
Blood|June 17, 2017
JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AMLRiikka Karjalainen, Tea Pemovska, Mihaela Popa, et al.
Pageof 5